N4 Pharma PLC Notification of Intention to Grant Patent (8017O)
February 11 2021 - 4:30AM
UK Regulatory
TIDMN4P
RNS Number : 8017O
N4 Pharma PLC
11 February 2021
11 February 2021
N4 Pharma plc
("N4 Pharma" or the "Company")
Notification of Intention to Grant Patent
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to announce that the University of
Queensland ("UQ") has been notified by the European Patent Office
("EPO") of its intention to grant a European Patent in relation to
Nuvec(R) specifically in respect of its composition, particulate
materials and methods for making the particulate materials (the
"Patent"). N4 Pharma has the exclusive worldwide rights to Nuvec(R)
for therapeutic uses in humans and animals.
Having received the notification the next steps prior to formal
grant will require UQ to confirm the particulars and translations
with the EPO prior to publication of the grant after which the
Patent will be validated on a country by country basis throughout
Europe as determined by UQ and the Company. This process, resulting
in the full grant of the Patent in each chosen territory, should
take six to eight months.
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"The receipt of the intention to grant the primary Patent in
respect of Nuvec(R) for Europe is a key milestone for the Company
and should see other key jurisdictions where patents remain pending
for Nuvec(R) follow suit.
"The timing is especially relevant as we undertake our most
comprehensive in vivo studies to date starting with Nuvec(R) loaded
with the Coronavirus plasmid currently underway and the shortly to
commence study incorporating our various learnings from the
optimisation work over the last eighteen months.
"It is also particularly important as discussions with potential
collaborators continue. We look forward to providing a full update
on all our work streams, including our oral and oncology work, when
we publish our full year results for the year ended 31 December
2020 which is expected to be towards the end of February / early
March."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker/Zoe Alexander
IFC Advisory Ltd Tel: +44(0)20 3934
Financial PR 6630
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFLIFSILLIL
(END) Dow Jones Newswires
February 11, 2021 05:30 ET (10:30 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Mar 2024 to Apr 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2023 to Apr 2024